Literature DB >> 6089158

Alpha up-beta down adrenergic regulation: a possible mechanism of action of antidepressant treatments.

J Vetulani, L Antkiewicz-Michaluk, A Rokosz-Pelc, A Pilc.   

Abstract

The presently reported findings: that spaced electroconvulsive treatment increases the density of alpha-1 adrenoceptor in the spinal cord as well as in the cerebral cortex of the rat, that treatment with various classes of antidepressant drugs, including antidepressant neuroleptics, affects in a similar manner alpha-adrenoceptors, elevating within 2 weeks the density of alpha-1, and depressing the density of alpha-2 subpopulation, and that prolonged imipramine treatment in investigated strains of rats does not depress the beta adrenoceptor density within 3 weeks, but only after 6-week-treatment such an effect is observed, are discussed together with our earlier results. It is suggested that the first effect of an antidepressant therapy may be a transient upregulation of alpha-2 adrenoceptors causing a decrease in noradrenaline utilization, but this is followed rapidly by an upregulation of alpha-1 adrenoceptors and depression of density of alpha-2 adrenoceptors. Eventually, adaptive beta adrenoceptor down-regulation follows. The final effect of an antidepressant therapy is a specific facilitation of neurotransmission regulated by alpha-1 adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6089158

Source DB:  PubMed          Journal:  Pol J Pharmacol Pharm        ISSN: 0301-0244


  8 in total

Review 1.  Ketamine: The final frontier or another depressing end?

Authors:  Omar K Sial; Eric M Parise; Lyonna F Parise; Tamara Gnecco; Carlos A Bolaños-Guzmán
Journal:  Behav Brain Res       Date:  2020-02-01       Impact factor: 3.332

2.  Effect of repeated treatment with antidepressant drugs and electroconvulsive shock (ECS) on [3H] prazosin binding to different rat brain structures.

Authors:  G Nowak; E Przegaliński
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

Review 3.  Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  R J Milne; K L Goa
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

4.  Regulation of Calcium-Independent Phospholipase A2 Expression by Adrenoceptors and Sterol Regulatory Element Binding Protein-Potential Crosstalk Between Sterol and Glycerophospholipid Mediators.

Authors:  Wee-Siong Chew; Wei-Yi Ong
Journal:  Mol Neurobiol       Date:  2014-12-09       Impact factor: 5.590

5.  Inhibition of presynaptic alpha-2-adrenoceptor and opioid receptor agonist responses in the rat vas deferens by chronic imipramine treatment.

Authors:  R A Keith; A I Salama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

6.  Biochemical and pharmacological effects of fluperlapine on noradrenaline and acetylcholine systems in some rodent, bovine and crustacean preparations.

Authors:  C Rüdeberg; S Urwyler; C Schulthess; P L Herrling
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-04       Impact factor: 3.000

Review 7.  Zinc in the Monoaminergic Theory of Depression: Its Relationship to Neural Plasticity.

Authors:  Urszula Doboszewska; Piotr Wlaź; Gabriel Nowak; Maria Radziwoń-Zaleska; Ranji Cui; Katarzyna Młyniec
Journal:  Neural Plast       Date:  2017-02-19       Impact factor: 3.599

8.  Analysis of Density Changes of Selected Brain Receptors After a 14-Day Supply of Chromium(III) and Evaluation of Chromium(III) Affinity to Selected Receptors and Transporters.

Authors:  Anna Piotrowska; Agata Siwek; Małgorzata Wolak; Gabriel Nowak
Journal:  Biol Trace Elem Res       Date:  2019-11-16       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.